TP53 Gene Mutations in Canine Osteosarcoma

Authors: 
JOLLE KIRPENSTEIJN, Prof., DVM, PhD, Diplomate ACVS and ECVS 1 , MARJA KIK, DVM, PhD 1 , ERIK TESKE, DVM, PhD, Diplomate ECVIM-CA 1 , and GERARD R. RUTTEMAN, DVM, PhD, Diplomate ECVIM-CA 1
Volume: 
37
Number: 
6
Pages: 
454-60
Journal: 
Vet Surg
Date: 
2008

ABSTRACT
Objective—To investigate mutations of the TP53 gene in canine osteosarcoma (OS).
Study Design—Clinical historic cohort study.
Animals—Client-owned dogs.
Methods—OS (n=59) were screened for mutations of the complete TP53 gene using polymerase chain reaction and the mutation was analyzed by single-strand conformational polymorphism. Clinical outcome of dogs with TP53-mutated OS were compared with dogs with OS without a mutation after complete surgical excision of the primary tumor.
Results—TP53 gene mutations were observed in 24 of 59 (40.7%) OS; 3 mutated OS had 2 mutations. The alterations consisted mainly of point mutations (74%). Dogs with mutated OS had a significantly shorter survival time (ST) after surgery than dogs with normal tumor TP53 gene expression (P=.03). Other significant prognosticators for ST and disease-free interval included elevated serum alkaline phosphatase (P<.01) and tumor grade (P=.01).
Conclusion—TP53 genetic mutations are common in canine OS and may have a prognostic value.
Clinical Relevance—Mutations of the TP53 gene may influence survival and should be considered when evaluating canine OS.

Small animal: